A Phase 1, Open-label, Single Dose, Parallel Group Study To Evaluate The Pharmacokinetics Of Glasdegib (Pf-04449913) In Subjects With Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2018
At a glance
- Drugs Glasdegib (Primary)
- Indications Acute myeloid leukaemia; Cancer; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Glioblastoma; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 26 Sep 2018 Status changed from recruiting to completed.
- 30 Aug 2018 Planned End Date changed from 30 Sep 2018 to 19 Sep 2018.
- 30 Aug 2018 Planned primary completion date changed from 30 Sep 2018 to 28 Aug 2018.